AMAG Pharmaceuticals’ Feraheme: The Next Billion Dollar Drug
August 3, 2009 by
Filed under Articles
On June 30, 2009, the FDA approved Feraheme for the treatment of anemia in chronic kidney disease (CKD), both in pre-dialysis patients and those undergoing dialysis. Feraheme, sold by AMAG Pharmaceuticals (AMAG), received a clean label without any black box warnings. Now that Feraheme has been approved, the key question for investors is what the market opportunity is and how quickly it will be achieved.
Background on Feraheme
More Information: